ASGE Annual GI Advanced Practice Provider Course (On-Demand) - Clinical Case-Based Learning (Day Two) | April 2023-NordICC Trial and CRC Screening

Pdf Summary

The NordICC Trial and Colorectal Cancer Screening: What Every APP Needs to Know<br /><br />This document provides an overview of the NordICC Trial and its implications for colorectal cancer (CRC) screening. The trial aimed to quantify the benefits of colonoscopy in population screening and found that the risk of CRC was reduced by 18% over 10 years with colonoscopy screening. However, the reduction in CRC death was not significant.<br /><br />The article emphasizes that colonoscopy is the best screening test for CRC if it gets done. It discusses other screening tests such as the fecal immunochemical test (FIT) and multitarget stool DNA tests (MT-sDNA), highlighting their advantages and disadvantages. It also explains that nearly 30% of endoscopists in the trial did not meet the recommended adenoma detection rate of 25%.<br /><br />The media response to the trial is highlighted, with various news networks and health news outlets covering the study. The importance of media response is emphasized, as patients and healthcare professionals may have questions about the study and its implications.<br /><br />The document provides key information for APPs (Advanced Practice Providers) to know about the NordICC Trial. This includes details about the participation rate in screening endoscopy and the estimated reduction in CRC and CRC death with colonoscopy. It also discusses the operator dependency of colonoscopy and suggests that certain patients should not undergo FIT or MT-sDNA.<br /><br />For patients, the document explains that the study does not detract from the overwhelming data supporting colonoscopy as a life-saving test. It emphasizes the importance of follow-up colonoscopy if FIT or MT-sDNA tests are positive and outlines the recommended screening intervals for average-risk individuals.<br /><br />Referring physicians are advised on the importance of adenoma detection rate and its association with future CRC and CRC death reduction. The document also emphasizes the value of colonoscopy as the only test that detects and removes adenomas.<br /><br />In summary, the document highlights the results of the NordICC Trial, provides information on its limitations, and stresses the need for effective communication between GI experts, patients, and referring physicians. It also provides resources for APPs to further their education in this area.

Asset Subtitle

Joseph Vicari, MD, MBA, FASGE

Keywords

NordICC Trial

colorectal cancer screening

colonoscopy

CRC risk reduction

FIT

MT-sDNA

adenoma detection rate

media response

APPs

communication